News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
744,821 Results
Type
Article (53271)
Company Profile (363)
Press Release (691187)
Section
Business (217669)
Career Advice (2856)
Deals (37604)
Drug Delivery (107)
Drug Development (86395)
Employer Resources (181)
FDA (17133)
Job Trends (16072)
News (369807)
Policy (35965)
Tag
Academia (2884)
Alliances (53115)
Alzheimer's disease (1319)
Approvals (17047)
Artificial intelligence (149)
Bankruptcy (378)
Best Places to Work (12116)
Biotechnology (239)
Breast cancer (129)
Cancer (1160)
Cardiovascular disease (107)
Career advice (2396)
Cell therapy (258)
Clinical research (68461)
Collaboration (410)
Compensation (202)
COVID-19 (2743)
C-suite (105)
Data (1154)
Diabetes (162)
Diagnostics (6502)
Drug pricing (95)
Earnings (87802)
Employer resources (158)
Events (117223)
Executive appointments (326)
FDA (17690)
Funding (366)
Gene therapy (196)
GLP-1 (667)
Government (4784)
Healthcare (19970)
Infectious disease (2832)
Inflammatory bowel disease (118)
Interviews (549)
IPO (16888)
Job creations (4331)
Job search strategy (1988)
Layoffs (467)
Legal (8902)
Lung cancer (188)
Manufacturing (192)
Medical device (13824)
Medtech (13829)
Mergers & acquisitions (20771)
Metabolic disorders (450)
Neuroscience (1620)
NextGen Class of 2024 (7139)
Non-profit (4877)
Northern California (1509)
Obesity (259)
Opinion (228)
Patents (111)
People (61443)
Phase I (21167)
Phase II (30013)
Phase III (22522)
Pipeline (466)
Postmarket research (2957)
Preclinical (9106)
Radiopharmaceuticals (248)
Rare diseases (238)
Real estate (6559)
Regulatory (23673)
Research institute (2562)
Resumes & cover letters (453)
Southern California (1325)
Startups (3907)
United States (13965)
Vaccines (621)
Weight loss (204)
Date
Today (140)
Last 7 days (752)
Last 30 days (3886)
Last 365 days (37296)
2024 (34212)
2023 (41746)
2022 (52980)
2021 (57655)
2020 (56527)
2019 (49807)
2018 (37729)
2017 (34734)
2016 (34701)
2015 (40732)
2014 (34839)
2013 (30211)
2012 (32196)
2011 (32810)
2010 (31014)
Location
Africa (940)
Arizona (205)
Asia (43152)
Australia (7633)
California (3410)
Canada (1305)
China (258)
Colorado (152)
Connecticut (158)
Europe (94397)
Florida (468)
Georgia (119)
Illinois (373)
Indiana (208)
Kansas (98)
Maryland (606)
Massachusetts (2698)
Michigan (162)
Minnesota (287)
New Jersey (982)
New York (977)
North Carolina (769)
Northern California (1509)
Ohio (142)
Pennsylvania (855)
South America (1324)
Southern California (1325)
Texas (477)
Washington State (378)
744,821 Results for "humanigen formerly known as kalobios pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
StimCell Energetics Inc. (Formerly “Cell MedX Corp.”) Announces Major Corporate Updates and Rebranding
November 4, 2024
·
3 min read
BioMidwest
New Cohort Study Data Shows Baxter’s Expanded Hemodialysis – Known as HDx Therapy – Is Associated With Approximately 25% Lower Mortality Rate for up to Four Years
Baxter International Inc. announced new data showing expanded hemodialysis, known as HDx therapy, enabled by Theranova dialyzer, was associated with an approximately 25% lower all-cause mortality risk for up to four years when compared to high-flux hemodialysis.
May 29, 2024
·
5 min read
Layoffs
Marinus Pharmaceuticals Lays Off 45% of Employees
The November layoffs are the second known workforce reduction this year for Marinus Pharmaceuticals, which previously announced disappointing Phase III results for ganaxolone in two clinical trials.
November 14, 2024
·
1 min read
·
Angela Gabriel
Press Releases
Bexion Pharmaceuticals, Inc. Announces Completion of Enrollment in Open Label Portion of Phase 1b/2 ASIST Study in mCRC
November 18, 2024
·
3 min read
Drug Development
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis
89bio, Inc. today announced the initiation of its Phase 3 ENLIGHTEN Program evaluating the efficacy and safety of pegozafermin in patients with metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH).
March 12, 2024
·
8 min read
Press Releases
Parabilis Medicines™ – Formerly FogPharma – Announces New Company Name and Unveils AI- and Physics-Based Discovery Platform
October 28, 2024
·
3 min read
Press Releases
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).
July 1, 2024
·
5 min read
Biotech Beach
Allez Health Announces $60 Million Capital Raise
Allez Health Inc., formerly known as Zense-Life Inc., an emerging biosensor venture founded by proven experts in the continuous glucose monitoring space, announced a $60 million Series A+ financing.
May 22, 2024
·
2 min read
Pharm Country
Humanigen Announces First Participant Dosed in RATinG Trial of Lenzilumab for Early Treatment of Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation
Humanigen, Inc. (OTC Pink: HGEN), a clinical-stage biopharmaceutical company, today announced successful dosing of the first participant in the RATinG trial of lenzilumab
August 7, 2023
·
7 min read
Humanigen Presents Promising New Hematologic Data from PREACH-M Trial for Chronic Myelomonocytic Leukemia Treatment at the 2023 European Hematology Association Congress
Humanigen, Inc. (Nasdaq: HGEN) today extended previously reported results by presenting additional, statistically significant hematologic improvements and reductions in inflammatory markers from lenzilumab, its investigational drug
June 9, 2023
·
14 min read
1 of 74,483
Next
